Literature DB >> 11680578

p21WAF1/CTP1 expression and hepatitis virus type.

H Wagayama1, K Shiraki, T Yamanaka, K Sugimoto, T Ito, K Fujikawa, K Takase, T Nakano.   

Abstract

Since p21WAF1/CIP1 (p21) is a universal inhibitor of cyclin-dependent kinases and is regulated transcriptionally by p53, which is activated by DNA stress, its expression reflects DNA stress in chronic hepatitis. Recently an association with both hepatitis B and C virus and the expression of p53 or p21 was reported. We analyzed p21 expression in 18 cases of HBV-associated chronic liver diseases and 32 cases of HCV-associated chronic liver diseases by immunohistochemical analysis, and investigated the possible association between hepatocyte p21 expression and hepatic inflammation, fibrosis, and especially hepatitis virus type. The p21-positive hepatocytes were more numerous in areas of intense inflammation and spotty necrosis and areas close to fibrosis, and they increased according to the degrees of grading and staging. The p21 labeling index (LI) in patients with liver cirrhosis was significantly higher than that in patients with chronic hepatitis of both hepatitis viral types (5.84 +/- 0.61 vs 12.0 +/- 0.83, P < 0.0001 in hepatitis B, 10.28 +/- 0.80 vs 15.6 +/- 1.09, P = 0.0004 in hepatitis C), Furthermore, the p21 LI was significantly higher in HCV-associated liver disease than in HBV-associated liver disease in every group (4.02 +/- 0.48 vs 7.74 +/- 0.96, P = 0.021 in low grade group, 7.35 +/- 0.46 vs 12.8 +/- 0.57, P < 0.0001 in high grade, 12.0 +/- 0.83 vs 15.6 +/- 1.09, P = 0.034 in liver cirrhosis). In, conclusion, p21 expression was up-regulated by the stress of inflammation and fibrosis and might be influenced by viral proteins in human chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680578     DOI: 10.1023/a:1011977923941

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Cell cycle. p21 inhibits cyclin shock.

Authors:  J Pines
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

Review 4.  Cell cycle control and cancer.

Authors:  L H Hartwell; M B Kastan
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

5.  Expression of cyclin-dependent kinase inhibitor p21 in human liver.

Authors:  G S Crary; J H Albrecht
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells.

Authors:  X Qiu; H J Forman; A H Schönthal; E Cadenas
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

7.  Association between reactive oxygen species and disease activity in chronic hepatitis C.

Authors:  N De Maria; A Colantoni; S Fagiuoli; G J Liu; B K Rogers; F Farinati; D H Van Thiel; R A Floyd
Journal:  Free Radic Biol Med       Date:  1996       Impact factor: 7.376

8.  Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP.

Authors:  A Suzuki; Y Tsutomi; K Akahane; T Araki; M Miura
Journal:  Oncogene       Date:  1998-08-27       Impact factor: 9.867

9.  Nitric oxide mediates hepatocyte injury.

Authors:  J H Wang; H P Redmond; Q D Wu; D Bouchier-Hayes
Journal:  Am J Physiol       Date:  1998-11

10.  Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells.

Authors:  J Schwaller; H P Koeffler; G Niklaus; P Loetscher; S Nagel; M F Fey; A Tobler
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more
  6 in total

1.  Hepatic progenitor cells in chronic hepatitis C: a phenomenon of older age and advanced liver disease.

Authors:  Johanna Delladetsima; Paraskevi Alexandrou; Konstantinos Giaslakiotis; Mina Psichogiou; Gregory Hatzis; Vana Sypsa; Dina Tiniakos
Journal:  Virchows Arch       Date:  2010-08-19       Impact factor: 4.064

2.  Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721.

Authors:  Jian-Hui Qu; Ming-Hua Zhu; Jing Lin; Can-Rong Ni; Fang-Mei Li; Zhi Zhu; Guan-Zhen Yu
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

3.  Differential expression of cell cycle regulators in HCV-infection and related hepatocellular carcinoma.

Authors:  Azza E El Bassiouny; Mona M Nosseir; Mona K Zoheiry; Noha A Ameen; Ahmed M Abdel-Hadi; Ibrahim M Ibrahim; Suher Zada; Abdel-Hakeem Saad El-Deen; Nora E El-Bassiouni
Journal:  World J Hepatol       Date:  2010-01-27

4.  Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Authors:  Katharine M Irvine; Richard Skoien; Nilesh J Bokil; Michelle Melino; Gethin P Thomas; Dorothy Loo; Brian Gabrielli; Michelle M Hill; Matthew J Sweet; Andrew D Clouston; Elizabeth E Powell
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

5.  Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma.

Authors:  Mei-Fang Zhang; Zhi-Yi Zhang; Jia Fu; Yu-Feng Yang; Jing-Ping Yun
Journal:  J Transl Med       Date:  2009-12-22       Impact factor: 5.531

6.  Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis.

Authors:  Holger Willenbring; Amar Deep Sharma; Arndt Vogel; Andrew Y Lee; Andreas Rothfuss; Zhongya Wang; Milton Finegold; Markus Grompe
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.